Home
Pharmanovia

Pharmanovia Market Share Analysis for July 2026

Basildon - (Hybrid role: 3 days office, 2 days home per week)

Health > Biotechnology and Pharmaceuticals

Domainpharmanovia.com

Year Founded2013

Employees201 - 500

Annual Revenue$10M - $15M

Pharmanovia

Pharmanovia (including company regionals)

pharmanovia.com

See more website traffic and engagement information

Pharmanovia Revenue up to July 2026 is 10M - 15M

revenue generated by Pharmanovia top domains

Pharmanovia top domains revenue over 3 years

Revenue for Pharmanovia top domains

pharmanovia.com10M - 15M

See more with Sales Intelligence

Total visits to Pharmanovia's top domains

Understand Pharmanovia market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

pharmanovia.com9.9K

See more with Sales Intelligence

Avg. visit duration in Pharmanovia's top domains

Analyze Pharmanovia engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

pharmanovia.com00:02:31

See more with Sales Intelligence

Avg. pageviews on Pharmanovia's top domains

See how Pharmanovia keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

pharmanovia.com4.81

See more with Sales Intelligence

Pharmanovia top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Pharmanovia

These are the website technologies, by industry, used by Pharmanovia top domains

Conversion & Analytics (3)

Google Analytics

Email Services (3)

Microsoft Exchange Online

Mobile (3)

Meta Viewport

Widget (3)

Twemoji

More Technologies

8

See all

News & Signals from Pharmanovia

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsPharmanovia, company is developing senaparib for maintenance monotherapy on Aug 3rd '26.Under the agreement, Pharmanovia will receive exclusive rights to manufacture, develop and commercialize senaparib for maintenance monotherapy in adults with advanced epithelial high-grade ovarian, fallopian tube and primary peritoneal cancer across 66 countries.

NewsIMPACT Therapeutics was planning to partner with Pharmanovia, company on Jul 31st '26.IMPACT will work closely with Pharmanovia to advance the commercialisation of senaparib in the collaboration territories.

NewsPharmanovia, company sold assets to CNX Therapeutics Ltd. on Apr 2nd '26.London, England - Thursday 2 April: CNX Therapeutics Limited ("CNX Therapeutics"), a specialty pharmaceutical company focused on improving patient access to essential medicines, today announced it has acquired the rights to Tacrolimus 5 mg/ml concentrate for solution for infusion from Pharmanovia.